Moderna (NASDAQ: MRNA) reported Q2 EPS of $5.24, $0.70 better than the analyst estimate of $4.54. Revenue for the quarter came in at $4.7 billion versus the consensus estimate of $4.07 billion.

For earnings history and earnings-related data on Moderna (MRNA) click here.